Upfront Immunotherapy for Metastatic Kidney Cancer
0 Views
administrator
06/26/23
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
-
Category
Show more
Facebook Comments
No comments found